Alzheimer disease (AD) 
Introduction

G protein-coupled receptor kinases (GRKs), like GRK2, are cytosolic proteins that are known to contribute to the adaptation of the heptahelical G protein-coupled receptors (GPCRs) and to regulate downstream signals through these receptors. GPCRs mediate the action of messengers that are key modulators of cardiac and vascular cell function
. To date, seven mammalian serine/threonine protein GRKs, which comprise the GRK family, have been described and six members cloned. GRK2 and 3 form the second subfamily, namely, ␤-adrenergic receptor kinase (␤ARK) subfamily, members of which are known to phosphorylate and regulate agonist-occupied or constitutively active GPCRs [2] . The [3] .
We [5] [6] [7] . We further hypothesize that GRK2 plays a role in these deleterious processes [4] . Additionally, the involvement of chronic brain hypoperfusion (CBH) and physical distortion of the surrounding tissue exacerbate this imbalance and more than likely contribute to the collapse of post-ischaemic/hypoxic vessels. Sustained hypoperfusion and oxidative stress, which are primary features of aged brain tissues during the prodromal stages of AD [5] [6] [7] [8] .) These findings raise questions regarding the direct relationship between oxidative stress, energy failure (e.g. mitochondrial lesions) or metabolic insufficiency, neuronal and vascular damage, BBB breakdown and A␤ deposition during the maturation of AD-like pathology [9, 10] . [6, 11] . (1) interfere with NO function and endothelial relaxation by reducing its bioavailability (through ROS scavenging), (2) actually increase the amount of oxidative stress levels through the production of the potent oxidant peroxynitrite, (3) impair endothelial barrier function and promote leukocyte adhesion and (4) induce alterations in normal vascular function thereby further decreasing cerebral blood flow (CBF) [12] . It appears that transient GRK2 activity correlates with compensatory changes to oxidative stress and arterial occlusion, including changes in ET-1 expression [9, 10] . Although [4] . Increasing evidence for the roles of GRKs and angiotensin 1 and 2 (AT1 and AT2) in hypertension, stroke, and heart disease and association between these receptors and ligands in heart disease and AD [13] as well as early amyloid-␤ (A␤) accumulation in vitro [14] and our in vivo work with models of hypoperfusion [4] [4, 15] .
speculate that an imbalance in the activity of nitric oxide synthase (NOS) isoforms, endothelin-1 (ET-1) and oxidative stress, as evidenced by several biomarkers of this damage, along with mitochondrial DNA (mtDNA) aberrations and the imbalance of mitochondrial enzymes in vascular wall cells and in neurons, leads to an inadequacy in the antioxidant response capacity to sufficiently abate metabolic and oxidative insults which are two key initial features in the brains of stroke and AD patients
, also may further stimulate the expression of various NOS species and subsequent ET-1 in brain cells and probably increase the accumulation of oxidative stress products, thereby contributing to blood-brain barrier (BBB) breakdown and brain parenchymal cell damage (For a more in-depth discussion regarding the interactions of each of these factors, please see our previous work
Normal aging and sporadic, late-onset AD have many features in common, with AD-like symptoms manifesting only when certain quantitative levels of damage attributed to risk factors such as metabolic and oxidative stress, as well as those associated with impaired cerebral perfusion (e.g. cardiovascular and cerebrovascular diseases including hypo-& hypertension and stroke) breech the body's ability to adequately cope with further insults
Under conditions associated with advanced aging such as those mentioned above, any imbalance in the activity of NOS isoforms, ET-1 and oxidative stress can lead to a potential and very destructive positive feedback loop in which increased levels of reactive oxygen species (ROS)
General features of GRKs
GRK function and interaction is complicated and important, compelling an active area of research interest. GRKs are known to regulate numerous receptor functions in both the brain and myocardium [16] . General features of GRK interaction with GPCRs lead to complex regulatory mechanisms that modulate receptor responsiveness and underlie important physiologic phenomena, including signal integration and desensitization [17] . GRKs 
Expression patterns of GRK2
The various GRK subtypes differ in their localization, regulation and mode of action. Many GRKs have been found highly expressed in heart, brain and other tissues. In rat and hamster [19] , they are known to regulate numerous receptor functions in both the brain and myocardium [20] . Desensitization and resensitization of a wide variety of GPCRs are processes involved in numerous brain functions and GRK2 expression is increased in the developing rat brain, which is consistent with an involvement in brain maturation processes [21] . The expression in the developing brain and in AD, which is also characterized by ectopic expression of a multitude of cell cycle markers and proteins that are involved in cell division, can be seen as an apparent ontogenic recapitulation as well [22] . These same analogies have been considered in the parallels of AD and cancer [23] [24] .
GRK2 has been well-characterized in the heart, where the onset of congestive heart failure (CHF) is associated with characteristic changes in myocardial expression of GRK2 and is known to significantly contribute to myocardial regulation and function in the failing heart [25] . Signalling through cardiac ␤ adrenergic receptors (␤ARs) is significantly impaired in many cardiovascular disorders, including CHF. Further, elevated levels of GRK2 mRNA and GRK2 activity have been reported in human left ventricle explants from heart failure patients [26] . In the heart, ␤ARs control numerous trophic responses to the catecholamine neurotransmitters, norepinephrine and epinephrine. Heart failure onset is characterized by reduced responsiveness to ␤-adrenoreceptor in cardiac tissues [27] and by changes in the expression of GRK2 or ␤-adrenoreceptor kinase1 (bARK1) [28] . When ␤-adrenoreceptor responsiveness was examined in a completely developed reperfused myocardial infarction model, higher levels of tissue catecholamines and GRK2 were observed in the ischaemic epicardium [29] . It was found that the density of the ␤-adrenoreceptor in the viable ischaemic regions can be modified by GRK2 and catecholamines. Conversely, cardiopulmonary intervention was found to decrease GRK expression [30] . [31] , portal hypertension [32] and in other cells and tissues in these conditions, such as lymphocytes [33] . [35] . Further, the processes involving internalization are known to lead to ERK activation as is the case of the ␤(2)AR and lysophosphatidic acid receptor [36] .
GPCR desensitization is emerging as an important feature of several cardiovascular diseases. GRK2 plays a key role in the regulation of a variety of these receptors and, at the promoter level, cardiac muscle expression is altered in pathological situations such as in CHF
GRKdependent receptor desensitization, and regulation of ␤AR and other GPCRs, is a rapid process, which appears to involve agonistpromoted receptor phosphorylation by GRKs. GRK-mediated receptor phosphorylation promotes the binding of arrestin proteins, such as ␤-arrestin [34]. ␤-arrestin binding uncouples GPCRs from their respective G proteins by sterically blocking receptor coupling to G proteins. These same regulatory proteins also regulate GPCR endocytosis, which then involves the processes of transient receptor internalization, intracellular trafficking and resensitization
Consequently, the ␤-arrestins play a crucial role in regulating the responsiveness of many GPCRs. GRK2, along with beta-arrestin, also play a key role in resensitizing GPCRs by allowing its dephosphorylation and recycling. Data by Mayor and colleagues indicate
that besides the uncoupling function of ␤-arrestin, which together with GRK directly participates in ␤(2)AR sequestration, may provide the trigger for resensitization [17] . GRK2 levels in myocardium and lymphocytes may be associated with ␤-AR dysfunction and heart failure severity.
Signalling [42] in response to hypertrophic stimuli in vitro and in the development of heart failure in vivo [43, 44] . Nevertheless, the endothelin A and B receptors (ETA-R and ETB-R) undergo desensitization, most likely also through GRK2 [45] [52] . Further, it has been shown that phosphorylation of GRK2 by MAPK also triggers turnover and GRK2 degradation through the proteasome pathway. GRK2 is targeted for proteolysis by ␤-arrestin function [53] . Therefore, GRK2 may play a very important role in AD pathogenesis mechanisms through oxidative stress and mitochondrial dysfunction. [16] and the differential GRK 2 expression in compensated hypertrophy and heart failure after myocardial infarction in the rat. Moreover, GRKs regulate metabotropic glutamate receptor 5 function and expression [54] , which has also been implicated in AD pathogenesis and GRKs may offer a mechanism for desensitization of this receptor isoform.
GRK studies in AD and CBH
Studies of the details and consequences of GRK's mechanisms have focused heavily on the original beta-adrenoreceptor kinase (beta-ARK) family (GRK2 and GRK3) and, in particular, on phosphorylation-dependent recruitment of adaptor proteins such as the beta-arrestins. Several lines of evidence implicate GRK and beta-arrestin expression in AD and after cerebral hypoxia/ ischaemia (HI)
The main experimental goal of our previous study was to investigate and better clarify the relationship between GRK2, vascular lesions and the development of pathology in a CBH model and AD, at the cellular and subcellular level [4] . In that regard, we examined a connection between vascular damage and predisposing factors for AD, where we explored the changes in brain distribution of GRK2 in microvessel wall cells and neurons using a CBH model and in AD cases. Our previous studies and those of others have reported that CBH will result in a 22-30% reduction of hippocampal blood flow that will stabilize after several weeks without further reduction [55] [56] [57] . This model is relevant to examining the physiopathology of AD and stroke and enables exploration of the relationship between vascular events and AD.
Our study is the first to show ultrastructural localization and overexpression of GRK2 during the early stages of damage in aged human and AD cases (see Figs. 1 show abundant GRK2 immunopositive reactivity (Fig. 2) . The intensity of the reaction varied from cell to cell and within cellular compartments as well (Figs. 1 and 2) [4, 67] . [14] . This led to reduced membrane GRK2/5, which subsequently led to retarded GPCR desensitization, prolonged GPCR signalling, and cellular supersensitivity to GPCR agonists [14] . [55, 58] . [8-10, 59, 60] .
and 2), and also in a our 2-VO model of CBH (see Figs. 3-5). This overexpression is an early event, occurring at prodromal stages, before and up to a point when the damage is reversible. Usually, GRK2 immunoreactivity was found to be associated with damaged cellular compartments, especially mitochondria and/or mitochondria-derived lysosomes or granular/vacuolar degenerative structures (see Figs. 1 and 2). The immunopositive reactivity was observed in damaged vessel wall cells and their subcellular compartments (Figs. 1 and 2). We have found that neurons that contain neurofibrillary tangles (NFT)
Fig. 1 Subcellular localization of GRK2 immunoreactivity detected by using preembedding immunogold decoration in hippocampus of aged matched control (A, B) and AD brain (C, D). (A and B) The neuronal cell body from the age-matched control brain hippocampal tissue shows the presence of GRK2 containing gold particles (arrows) attached to the external membrane of partially damaged mitochon dria. GRK2 immunoposi tive gold particles localized in the matrix of damaged mitochondria and Golgi cistern. ϫ30,000 and ϫ40,000, respectively, A and B. (C) Hippocampal tissue from the AD brain shows that the neuronal cell body is characterized by the presence of large number of mitochondria-derived lysosomes (M), and disperse distribution of GRK2 positive gold particles (arrows). ϫ6000. (D) Glial cell body from the AD brain tissue shows clusters of GRK2-immunoreactivity in the matrix
A parallel study reported abnormal GRKs in vitro for early stages of AD, which is associated with early amyloid beta (A␤) accumulation in vitro and showed that subthreshold A␤ pretreatment disrupts binding of GRKs to activated GPCRs
The same group went on to report in a transgenic mouse model of AD, where the double-mutant form of APP695 is overexpressed under the regulation of a prion promoter, the overexpression of GRK2, and to a lesser extent GRK5, occurred in the cytosolic versus membrane fractions from hippocampal and cortical brain homogenates with increasing age and plaque deposition. While the in vitro observation is quite likely to occur within microglia, the increase in the overexpression of GRK2 and GRK5 in the cytosol of neurons was not differentiated in this study. Nevertheless, we report the subcellular localization of GRK2 in neurons and the earlier involvement of vascular lesions in vivo as a key event in this process and, thus, in the development of human AD and AD-like pathology. Data to support this notion have been explored in various rat models
In this regard, we have demonstrated that abnormal mitochondria (mitochondria with electron dense matrix and mitochondrial-derived lysosomes) and lipofuscin appear to be features of damaged hippocampal neurons in aged Tg (ϩ) mice
Fig. 2 The ultrastructural localization of GRK2 immunopositive gold particles in postmortem human AD (A) and age-matched control brain (B, C) tissues. (A) The GRK2 immunopositive containing gold particles in the matrix of perivascular pericytes (indicated by single thick arrows) but not in the cytoplasmic matrix of severely damaged vascular endothelium (EC), ϫ40,000. (B and C) The neurons close to perivascular regions show the presence of GRK2containing gold particles in their matrix, where most gold particles were associated with the neurofibrillary tangle (NFT)-like structures (arrows
Our in vivo data discussed in light of another study involving amyloid [14] [59, 61] . Our studies demonstrate an increase in GRK2 localization to the cytosol, but in particular to subcellular components and only those components with damage and/or pathology evident (see Figs. 1-5 has been implicated in other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) [64] . Thus, there are numerous parallels that can be drawn between the neurodegenerative and cerebrovascular disorders with heart disease and systemic vascular disorders, which drives home the important connection the role GRK can have in all disorders, particularly AD [65] .
In comparison to controls, ultrastructure in AD and animal models are predominated by abnormal mitochondria. Studies examining deleted mtDNA and mitochondrial-derived lysosomes in regions closely associated with lipofuscin suggest that proliferation, deletion and duplication of mtDNA occur in mitochondria in human AD and transgenic mouse models of neurodegeneration [8-10, 59, 60] . In situ hybridization with a chimeric mouse and human mitochondrial cDNA probes for the 5 kb common deletion indicate that the deletion is increased at least three-fold in AD cases as compared to controls and in yeast artificial chromosome (YAC) APP mouse hippocampus [8] [9] [10] 66] [68] . The connection to a cerebrovascular component to AD is further borne out in other rat studies, where differentially expressed cardiac GRK2 expression and activity has been found. Here, GRK2 expression has been reported to be inhibited in animals with cardiac hypertrophy without heart failure, whereas animals with heart failure had elevated GRK2 [16] . This expression pattern indicates differential regulation in hypertrophic non-failing and hypertrophic failing hearts. Nevertheless, it is now a commonly held belief that GRKs may likely become effective therapeutic targets for heart disease [37] and should be considered for AD or related neuropathology as well. [72] and in regulation of metabotropic glutamate receptor 5 function and expression [73] . Both of these receptors have been implicated in AD pathogenesis as well [74, 75] 
Conclusions
